SAN FRANCISCO, Nov. 9, 2017 /PRNewswire/ -- Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced that Ken Horne, chief executive officer, will present at the upcoming 2017 Biotech and Money Inv€$tival Showcase, organized in partnership with Jefferies LLC, and the Trout Group EU Company Showcase in London. In addition, Ken Horne will present an overview of the company platform and clinical development programs at the Piper Jaffray 29th Annual Healthcare Conference in New York. The company also plans to attend the Jefferies 2017 London Healthcare Conference taking place Nov. 15-16, 2017. Details of the presentations are as follows:
Biotech and Money Inv€$tival Showcase in partnership with Jefferies LLC
Date: Tuesday, Nov. 14, 2017Time: 1:15 p.m. GMTLocation: The Hilton Waldorf, London
The Trout Group EU Company Showcase
Date: Tuesday, Nov. 14, 2017Time: 4 p.m. GMTLocation: Davis Polk & Wardwell LLP, London
Piper Jaffray 29th Annual Healthcare Conference
Date: Wednesday, Nov. 29, 2017Time: 1:10 p.m. ESTLocation: Lotte New York Palace, New York
About Symic Bio
Symic Bio is a biopharmaceutical company developing novel matrix-targeting biotherapeutics, a new category of therapeutics focused on matrix biology. These biotherapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
Advertisement
Biotech and Money Inv€$tival Showcase in partnership with Jefferies LLC
Date: Tuesday, Nov. 14, 2017Time: 1:15 p.m. GMTLocation: The Hilton Waldorf, London
Advertisement
The Trout Group EU Company Showcase
Date: Tuesday, Nov. 14, 2017Time: 4 p.m. GMTLocation: Davis Polk & Wardwell LLP, London
Piper Jaffray 29th Annual Healthcare Conference
Date: Wednesday, Nov. 29, 2017Time: 1:10 p.m. ESTLocation: Lotte New York Palace, New York
About Symic Bio
Symic Bio is a biopharmaceutical company developing novel matrix-targeting biotherapeutics, a new category of therapeutics focused on matrix biology. These biotherapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
View original content:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-upcoming-conferences-in-london-and-new-york-300552719.html
SOURCE Symic Bio
